Treatments that prolong survival in metastatic CRPC (many identified since 2010) include Docetaxel (a taxane chemotherapy drug) Sipuleucel-T (a patient-derived vaccine designed to induce immunity against prostate cancer cells) Abiraterone (which blocks androgen synthesis in the tumor as well as in the testes and adrenal glands) Enzalutamide, darolutamide, apalutamide (which blocks binding of androgens to their receptors) Cabazitaxel (a taxane chemotherapy drug that may have activity in tumors that have become resistant to docetaxel) Radium-233 (which emits alpha radiation, recently found to prolong survival as well as prevent complications due to bone metastases in men with CRPC) PARP (poly [ADP-ribose]) inhibitors (olaparib, rucaparib) appear active in mCRPC patients with BRCA1/2 mutations Some data suggest that sipuleucel-T should be used at the earliest sign of CRPC.